Glaukos is a Laguna Hills-based company developing a medical device for treating glaucoma. Its core product is a stent designed to relieve eye pressure during cataract surgery. The company is focused on minimally invasive surgical treatment for glaucoma patients. Financially, Glaukos announced a $30M Series F funding round. No operating metrics or revenue figures were provided in the article. Additional strategic or product plans were not specified in the article. Glaukos is developing a medical device for the treatment of glaucoma. The company is based in Laguna Hills. On February 3, 2011, Glaukos raised $29.5M in a Series E round. The funding was led by Meritech Capital Partners, which contributed $16M, and included all prior investors. Prior investors listed in the round include Domain Associates, Frazier Healthcare Ventures, Interwest Partners, Montreux Equity Partners, Orbimed Advisors, and Versant Ventures. The Glaukos management team has previously been involved with firms such as Allergan, Advanced Medical Optics, Bausch & Lomb, Edwards Lifesciences, and Chiron.

Total raised

$60M

Funding rounds

2

Latest round

Series F

Latest activity

Feb 2013